Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV...
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count great...
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of t...
Among 382 patients with WHO-defined prefibrotic myelofibrosis (pre-PMF) followed for a median of 6.9...
In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment appro...
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with vari...
Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clini...
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with vari...
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV...
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count great...
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of t...
Among 382 patients with WHO-defined prefibrotic myelofibrosis (pre-PMF) followed for a median of 6.9...
In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment appro...
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with vari...
Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clini...
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with vari...
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses fiv...
Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV...